Study S002299

A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT06982859
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 95
Start: 2025-06-02
Primary completion: 2027-01
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus; Insulin Sensitivity
Interventions: DRUG:Retatrutide; DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J1I-MC-GZQG; CTIS:2024-518470-13-00

Registered primary outcomes

Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo [Baseline, Week 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.